دورية أكاديمية
أعرض في EDS

An Electronic Health Record-Integrated Application for Standardizing Care and Monitoring Patients With Autosomal Dominant Polycystic Kidney Disease Enrolled in a Tolvaptan Clinic: Design and Implementation Study.

التفاصيل البيبلوغرافية
العنوان: An Electronic Health Record-Integrated Application for Standardizing Care and Monitoring Patients With Autosomal Dominant Polycystic Kidney Disease Enrolled in a Tolvaptan Clinic: Design and Implementation Study.
المؤلفون: Chedid M; Hennepin Healthcare, Minneapolis, MN, United States., Chebib FT; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL, United States., Dahlen E; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, United States., Mueller T; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, United States., Schnell T; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, United States., Gay M; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, United States., Hommos M; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Scottsdale, AZ, United States., Swaminathan S; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Scottsdale, AZ, United States., Garg A; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, LaCrosse, WI, United States., Mao M; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL, United States., Amberg B; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, United States., Balderes K; Division of Information Technology, Mayo Clinic, Rochester, MN, United States., Johnson KF; Division of Information Technology, Mayo Clinic, Rochester, MN, United States., Bishop A; Division of Information Technology, Mayo Clinic, Rochester, MN, United States., Vaughn JK; Division of Information Technology, Mayo Clinic, Rochester, MN, United States., Hogan M; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, United States., Torres V; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, United States., Chaudhry R; Division of Community Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, United States., Zoghby Z; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
المصدر: JMIR medical informatics [JMIR Med Inform] 2024 May 01; Vol. 12, pp. e50164. Date of Electronic Publication: 2024 May 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: JMIR Publications Country of Publication: Canada NLM ID: 101645109 Publication Model: Electronic Cited Medium: Print ISSN: 2291-9694 (Print) NLM ISO Abbreviation: JMIR Med Inform Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Toronto : JMIR Publications, [2013]-
مستخلص: Background: Tolvaptan is the only US Food and Drug Administration-approved drug to slow the progression of autosomal dominant polycystic kidney disease (ADPKD), but it requires strict clinical monitoring due to potential serious adverse events.
Objective: We aimed to share our experience in developing and implementing an electronic health record (EHR)-based application to monitor patients with ADPKD who were initiated on tolvaptan.
Methods: The application was developed in collaboration with clinical informatics professionals based on our clinical protocol with frequent laboratory test monitoring to detect early drug-related toxicity. The application streamlined the clinical workflow and enabled our nursing team to take appropriate actions in real time to prevent drug-related serious adverse events. We retrospectively analyzed the characteristics of the enrolled patients.
Results: As of September 2022, a total of 214 patients were enrolled in the tolvaptan program across all Mayo Clinic sites. Of these, 126 were enrolled in the Tolvaptan Monitoring Registry application and 88 in the Past Tolvaptan Patients application. The mean age at enrollment was 43.1 (SD 9.9) years. A total of 20 (9.3%) patients developed liver toxicity, but only 5 (2.3%) had to discontinue the drug. The 2 EHR-based applications allowed consolidation of all necessary patient information and real-time data management at the individual or population level. This approach facilitated efficient staff workflow, monitoring of drug-related adverse events, and timely prescription renewal.
Conclusions: Our study highlights the feasibility of integrating digital applications into the EHR workflow to facilitate efficient and safe care delivery for patients enrolled in a tolvaptan program. This workflow needs further validation but could be extended to other health care systems managing chronic diseases requiring drug monitoring.
(© Maroun Chedid, Fouad T Chebib, Erin Dahlen, Theodore Mueller, Theresa Schnell, Melissa Gay, Musab Hommos, Sundararaman Swaminathan, Arvind Garg, Michael Mao, Brigid Amberg, Kirk Balderes, Karen F Johnson, Alyssa Bishop, Jackqueline Kay Vaughn, Marie Hogan, Vicente Torres, Rajeev Chaudhry, Ziad Zoghby. Originally published in JMIR Medical Informatics (https://medinform.jmir.org).)
References: Kidney Int Rep. 2020 Dec 31;6(3):755-767. (PMID: 33732990)
Am J Kidney Dis. 2017 Jul;70(1):122-131. (PMID: 28132720)
J Gen Intern Med. 2022 Nov;37(15):4002-4003. (PMID: 36036837)
Clin J Am Soc Nephrol. 2011 Jan;6(1):5-6. (PMID: 21127135)
Lancet. 1999 Jan 9;353(9147):103-7. (PMID: 10023895)
N Engl J Med. 2017 Nov 16;377(20):1930-1942. (PMID: 29105594)
Jt Comm J Qual Patient Saf. 2012 May;38(5):216-23. (PMID: 22649861)
Jt Comm J Qual Patient Saf. 2019 Nov;45(11):757-762. (PMID: 31526711)
Am J Med. 2018 Jun;131(6):661-668. (PMID: 29576192)
Am J Kidney Dis. 2016 May;67(5):792-810. (PMID: 26530876)
J Med Internet Res. 2021 Jul 6;23(7):e26817. (PMID: 34255674)
Mayo Clin Proc Innov Qual Outcomes. 2021 Feb;5(1):109-117. (PMID: 33521582)
JAMA. 2013 Aug 21;310(7):699-705. (PMID: 23989679)
JAMA Health Forum. 2022 Jun 5;3(6):e221852. (PMID: 35977248)
JAMA Netw Open. 2020 Jun 1;3(6):e207374. (PMID: 32568397)
J Med Internet Res. 2023 Mar 22;25:e40595. (PMID: 36947138)
Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1418-1427. (PMID: 28778854)
Ann Fam Med. 2017 Sep;15(5):419-426. (PMID: 28893811)
JAMA Netw Open. 2019 Aug 2;2(8):e199609. (PMID: 31418810)
Am J Kidney Dis. 2020 Nov;76(5):636-644. (PMID: 32682696)
BMC Nephrol. 2015 May 03;16:69. (PMID: 26024966)
J Am Med Inform Assoc. 2020 Apr 1;27(4):531-538. (PMID: 32016375)
Health Aff (Millwood). 2017 Apr 1;36(4):655-662. (PMID: 28373331)
Jt Comm J Qual Patient Saf. 2017 Jul;43(7):353-360. (PMID: 28648221)
Mayo Clin Proc. 2023 Jan;98(1):163-180. (PMID: 36603944)
Health Informatics J. 2022 Jul-Sep;28(3):14604582221113435. (PMID: 35829729)
BMC Nephrol. 2019 Mar 1;20(1):72. (PMID: 30823871)
J Am Soc Nephrol. 2015 Jan;26(1):160-72. (PMID: 24904092)
Am J Kidney Dis. 2021 Aug;78(2):282-292. (PMID: 33705818)
J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. (PMID: 30228150)
Ann Intern Med. 2006 May 16;144(10):742-52. (PMID: 16702590)
Mayo Clin Proc. 2022 Dec;97(12):2248-2258. (PMID: 36229269)
JAMA. 2009 Aug 19;302(7):790-1. (PMID: 19690313)
N Engl J Med. 2012 Dec 20;367(25):2407-18. (PMID: 23121377)
J Gen Intern Med. 2020 Feb;35(2):465-472. (PMID: 31797160)
فهرسة مساهمة: Keywords: autosomal dominant polycystic kidney disease; ADPKD; EHR; chronic disease; digital application; digital health solutions; drug-related toxicity; electronic health record; kidney disease; management; monitoring; polycystic kidney disease; tolvaptan
تواريخ الأحداث: Date Created: 20240508 Latest Revision: 20240512
رمز التحديث: 20240512
مُعرف محوري في PubMed: PMC11085039
DOI: 10.2196/50164
PMID: 38717378
قاعدة البيانات: MEDLINE
الوصف
تدمد:2291-9694
DOI:10.2196/50164